
    
      Patients in group A will receive 4 cycles of NK treatments within 8 months. Patients in group
      B will have no immunotherapy. Chemotherapy are available in both groups.The investigators
      want to evaluate the efficacy of combination of NK with chemotherapy in patients with
      treatment-refractory solid tumors
    
  